Strategic acquisitions CHS has aggressively expanded through multiple acquisitions (Stadco Polyproducts, Respan Products, Velmed Inc.) and US/Canada market growth, suggesting a strong appetite for integrated supplier partnerships and cross-sell opportunities across clinical categories.

North American focus With a stated strong focus on the North American market and recent expansion of offices and manufacturing capacity in Ontario and the US, there is potential to upsell on locally manufactured devices, rapid replenishment programs, and regionally tailored solutions.

End-to-end partner CHS positions itself as a trusted partner rather than a generic distributor, emphasizing connections to decision-makers and outcomes-driven product choices; this presents an opportunity to propose value-based bundles, service agreements, and training/implementation services to hospitals and non-acute settings.

Diverse product scope The broad portfolio across Respiratory, Anesthesia, Perfusion, Interventional Radiology, Biopsy, Diagnostic Imaging, Vascular Access, Infection Prevention and more indicates multiple entry points for cross-category SKUs, bundles, and bundled maintenance contracts with hospital sourcing teams.

Growth financing signals Funding and grants in 2022 to expand manufacturing capacity and emergency readiness, plus ongoing headcount growth, signal operational scaling; sales opportunities exist in modernization projects, capacity expansion, and emergency preparedness programs in healthcare facilities.